

12-08-00

A

PATENT

Attorney Docket No.: 5200.220-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL 636738823US  
Date of Deposit December 7, 2000

Sir:

This is a request for filing a divisional application under 37 C.F.R. 1.53(b) of

Applicant(s): Svendsen et al.

Title: Laccase Mutants

141 pages of specification 1 page of abstract

0 sheets of drawings

2 sheets of Executed Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: $8 - 20 = 0 \times 18 =$	\$0
Independent Claims: $8 - 3 = 5 \times 80 =$	\$400.00
Total Fee:	\$1110.00

Priority of Danish application no. 0222/97 filed on February 28, 1997 is claimed under 35 U.S.C. 119. A certified copy was submitted with U.S. Serial No. 09/032,315.

The benefit of application no. 09/396,260 filed on September 15, 1999, and application no. 09/032,315 filed on February 27, 1998, now U.S. Patent 5,985,818 in the U.S. is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

12/07/00  
JC965 U.S. PTO

JC962 U.S. PTO  
09/732350  
09/07/00

Reza Green, Reg. No. 38,475

Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

- 2 -

Attorney Docket No.: 5200.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231



Re: U.S. Patent Application for  
Title: Laccase Mutants  
Applicants: Svendsen et al.

Sir:  
Express Mail Label No. EL 636738823US  
Date of Deposit: December 7, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Information Disclosure Statement
6. Form PTO-1449
7. Sequence Listing (pages 117-135)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Carol McFarlane

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123